CRH Medical Corp. (CRH-T) Stock Predictions - Stockchase
WATCH LIST
88
CRH Medical Corp. (CRH-T)

ON STOCKCHASE SINCE Jul 2009

biotechnology/pharmaceutical

CRH Medical Corp.

CRH-T

43 watching          
Join the Discussion

CRH Medical Corp. (CRH-T) SAVE Apr, 19, 2019, 9:16 am

3.80 0.04 (1.06%)

What the experts are saying about CRH-T



  • All
  • Filtered
Signal Opinion Expert
COMMENT
CRH Medical Corp.(CRH-T) 

March 11, 2019

It's trending along now. Not worried about it. It'll be rangebound; it's currently right in the middle of this channel. Breaking below the range would be negative.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
It's trending along now. Not worried about it. It'll be rangebound; it's currently right in the middle of this channel. Breaking below the range would be negative.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Elliott Fishman

Director o, Trading Services Gro...

Price Price
$3.820
Owned Owned
Unknown

PARTIAL BUY
CRH Medical Corp.(CRH-T) 

January 28, 2019

A $4 stock that's chugging along. It's got a chance now and has room to move. Hold or buy a new half-position.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
A $4 stock that's chugging along. It's got a chance now and has room to move. Hold or buy a new half-position.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Elliott Fishman

Director o, Trading Services Gro...

Price Price
$4.090
Owned Owned
Unknown

TOP PICK
CRH Medical Corp.(CRH-T) 

November 30, 2018

This company is involved in colonoscopies and aggregates businesses in that space, mostly in the US. It trades at less than 10 times free cash-flow. He expects growth from organic tail winds in the procedure space. Acquisitions are done within existing cash flow. Yield 0%. (Analysts’ price target is $6.08)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
This company is involved in colonoscopies and aggregates businesses in that space, mostly in the US. It trades at less than 10 times free cash-flow. He expects growth from organic tail winds in the procedure space. Acquisitions are done within existing cash flow. Yield 0%. (Analysts’ price target is $6.08)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Steven Ko

President , Steven Ko...

Price Price
$4.640
Owned Owned
Yes

BUY
CRH Medical Corp.(CRH-T) 

April 5, 2018

He was long about a year ago.  It had a rough ride but he is long again now.  The valuation has become compelling.  Good balance sheet and debt not a problem. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He was long about a year ago.  It had a rough ride but he is long again now.  The valuation has become compelling.  Good balance sheet and debt not a problem. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Mann

CIO & Co-F, Edgehill Patners...

Price Price
$3.450
Owned Owned
Yes

COMMENT
CRH Medical Corp.(CRH-T) 

January 24, 2018

Their business has been cut back, which is why the stock price had dropped. Feels they continue to be in the "rinse and repeat" mode. They make an acquisition, amalgamate it, bring it into their operation, and increase the business through their marketing, and then go and make another acquisition. Management feels there is lots and lots of room for them to continue this way. The stock looks like it has built a bit of a base and is trying to move higher. Suspects the worst of the news is out, and the market will probably continue to warm up to it.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Their business has been cut back, which is why the stock price had dropped. Feels they continue to be in the "rinse and repeat" mode. They make an acquisition, amalgamate it, bring it into their operation, and increase the business through their marketing, and then go and make another acquisition. Management feels there is lots and lots of room for them to continue this way. The stock looks like it has built a bit of a base and is trying to move higher. Suspects the worst of the news is out, and the market will probably continue to warm up to it.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Bruce Campbell

President , Stone Castle Investm...

Price Price
$3.790
Owned Owned
No

COMMENT
CRH Medical Corp.(CRH-T) 

December 15, 2017

Had this in his Growth portfolio, and it just didn’t work out. A situation where a company gets oversold. It will probably have a good January bounce because of all the tax loss selling that has probably occurred over the last couple of weeks or months. He is having a hard time with this. Would like to support it on valuation, but in terms of execution it has issues with payor codes changing, and the revenue growth is largely beyond the company's control. They haven't handled the past year very well. He would put this in the "OK" category, but with 10,000 public companies to choose from, it is well low on his list.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Had this in his Growth portfolio, and it just didn’t work out. A situation where a company gets oversold. It will probably have a good January bounce because of all the tax loss selling that has probably occurred over the last couple of weeks or months. He is having a hard time with this. Would like to support it on valuation, but in terms of execution it has issues with payor codes changing, and the revenue growth is largely beyond the company's control. They haven't handled the past year very well. He would put this in the "OK" category, but with 10,000 public companies to choose from, it is well low on his list.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Peter Hodson

CEO & Head, 5i Research Inc....

Price Price
$3.010
Owned Owned
Unknown

WATCH
CRH Medical Corp.(CRH-T) 

December 4, 2017

He was one of the first buyers.  He sold half his position when it was disproportionately high and then the rest on the way down.  The market has lost confidence in management, who also sold a lot of shares in the $7 range.  If it broke through $3.30 on heavy volume he would take a good look but there are better options until then.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He was one of the first buyers.  He sold half his position when it was disproportionately high and then the rest on the way down.  The market has lost confidence in management, who also sold a lot of shares in the $7 range.  If it broke through $3.30 on heavy volume he would take a good look but there are better options until then.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Del Vicar

Portfolio , HollisWealth...

Price Price
$2.610
Owned Owned
No

COMMENT
CRH Medical Corp.(CRH-T) 

November 24, 2017

Has been badly beaten up. In 2014, revenues were about $11 million, and are now looking at about $100 million. BV is around $.85, so it is still trading at around 3X BV. The important thing is that insiders have been selling like crazy. When this happens, that is not a good sign. Not a contrarian stock to his way of thinking.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Has been badly beaten up. In 2014, revenues were about $11 million, and are now looking at about $100 million. BV is around $.85, so it is still trading at around 3X BV. The important thing is that insiders have been selling like crazy. When this happens, that is not a good sign. Not a contrarian stock to his way of thinking.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Benj Gallander

President, Contra the Heard Inv...

Price Price
$2.520
Owned Owned
No

DON'T BUY
CRH Medical Corp.(CRH-T) 

November 14, 2017

Thinks management got caught off guard with the Medicare/Medicaid changes. Listening to the calls, he didn’t have a lot of confidence. Their business model is a bit broken now. With the share price and valuation so low, they are not getting as much bang for their buck now. Heading into the tax loss season, this is probably going to be one of the big targets. He would sit on the sidelines, at least until the new year.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Thinks management got caught off guard with the Medicare/Medicaid changes. Listening to the calls, he didn’t have a lot of confidence. Their business model is a bit broken now. With the share price and valuation so low, they are not getting as much bang for their buck now. Heading into the tax loss season, this is probably going to be one of the big targets. He would sit on the sidelines, at least until the new year.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Ryan Modesto

Managing P, 5i Research...

Price Price
$1.920
Owned Owned
Unknown

COMMENT
CRH Medical Corp.(CRH-T) 

November 13, 2017

They are in the US mainly and partner with anesthesiologists, for gut surgeries.  There is a whole system in the US as to who can treat whom and what they will pay.  These guys have been hit because of lack of organic growth and the concern is whether the reduced amount the Medicaid is willing to pay will impact margins going forward.  He thinks it is overdone.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

They are in the US mainly and partner with anesthesiologists, for gut surgeries.  There is a whole system in the US as to who can treat whom and what they will pay.  These guys have been hit because of lack of organic growth and the concern is whether the reduced amount the Medicaid is willing to pay will impact margins going forward.  He thinks it is overdone.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Brendan Caldwel

President, Caldwell Securities...

Price Price
$2.080
Owned Owned
Unknown

PAST TOP PICK
CRH Medical Corp.(CRH-T) 

November 8, 2017

(A Top Pick Nov 16/16. Down 71%.) A few things happened. Have had 2 reimbursement cuts. Hasn’t affecting earnings yet, but it will. It’s been an acquisition story and they’ve been buying anaesthesiology clinics using their stock as currency. That becomes difficult now because of the low stock price.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick Nov 16/16. Down 71%.) A few things happened. Have had 2 reimbursement cuts. Hasn’t affecting earnings yet, but it will. It’s been an acquisition story and they’ve been buying anaesthesiology clinics using their stock as currency. That becomes difficult now because of the low stock price.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Bruce Campbell

President , Stone Castle Investm...

Price Price
$2.180
Owned Owned
No

DON'T BUY
CRH Medical Corp.(CRH-T) 

October 19, 2017

It has not done anything at all for him and is on a short leash.  It is drifting back now.  He would be concerned about tax loss selling soon.  There is value there but don’t start a position.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

It has not done anything at all for him and is on a short leash.  It is drifting back now.  He would be concerned about tax loss selling soon.  There is value there but don’t start a position.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Peter Hodson

CEO & Head, 5i Research Inc....

Price Price
$2.940
Owned Owned
Yes

TOP PICK
CRH Medical Corp.(CRH-T) 

October 4, 2017

Has been looking at this for over 2 years, and met management repeatedly. Was aware of the Short attack circulating this summer, which had some pretty interesting important points to make. When a share price goes from $12 to around $3, his view is that it was fully priced in and there was a big overreaction by the street. They are exclusively based in the US, and have a medical product that is used by gastroenterologists in the clinics, kind of a Trojan horse for them because they have the clinics that are using the medical product, so have a relationship with them. With a number of the clinics, they have effectively bought 50% of the clinic, which allows them to provide the anaesthesia services on behalf of the doctors who work there. A pristine balance sheet. (Analysts’ price target is $5.)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Has been looking at this for over 2 years, and met management repeatedly. Was aware of the Short attack circulating this summer, which had some pretty interesting important points to make. When a share price goes from $12 to around $3, his view is that it was fully priced in and there was a big overreaction by the street. They are exclusively based in the US, and have a medical product that is used by gastroenterologists in the clinics, kind of a Trojan horse for them because they have the clinics that are using the medical product, so have a relationship with them. With a number of the clinics, they have effectively bought 50% of the clinic, which allows them to provide the anaesthesia services on behalf of the doctors who work there. A pristine balance sheet. (Analysts’ price target is $5.)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jerome Hass

Portfolio , Lightwater Partners...

Price Price
$3.260
Owned Owned
Yes

SELL
CRH Medical Corp.(CRH-T) 

September 28, 2017

He exited this story.  He was a big bull.  It came back for stock specific stories.  Multiple compression resulted from short reports. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He exited this story.  He was a big bull.  It came back for stock specific stories.  Multiple compression resulted from short reports. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Peter Imhof

Vice Presi, AGF Investments Inc...

Price Price
$2.890
Owned Owned
No

HOLD
CRH Medical Corp.(CRH-T) 

September 18, 2017

Had a tremendous run up to about $12, but got completely blindsided, and it pulled back heavily. Got stopped out around mid-$6. Thinks they are going to be okay long-term. There were some issues with insider selling at higher levels. If you own, continue to hold as it looks like it has bottomed.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Had a tremendous run up to about $12, but got completely blindsided, and it pulled back heavily. Got stopped out around mid-$6. Thinks they are going to be okay long-term. There were some issues with insider selling at higher levels. If you own, continue to hold as it looks like it has bottomed.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Del Vicar

Portfolio , HollisWealth...

Price Price
$3.190
Owned Owned
No

Showing 1 to 15 of 88 entries
Successfully Saved Company
Successfully Saved Company
4+
JOIN THE DISCUSSION
4 comments in the last 7 days